XWELHealthcare · Diagnostics & Research

XWEL Stock Forecast: XWELL, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$1.04

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 22 Aug 2026 — in the lower half.

Market cap

$8.9M

Ticker Nerd rank

39 / 100

Median analyst target

—

Analysts covering

Revenue$6.6M−5.5% y/y

Operating income−$5.4M

Net income−$11.0M

Free cash flow−$5.0M

Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown

Ticker Nerd rank

XWEL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores XWELL, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

Size

Issuance

Growth

Volatility

Revisions

Quality

Momentum

Value

Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (12): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XWEL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XWEL, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Recent analyst actionsNewest first

Of the 9 most recent actions, 1 moved their price target up and 2 moved it down.

Date	Firm	Action	Rating	Target
17 Nov 2023	HC Wainwright & Co.	Maintains	Buy	$1.00 → $7.00
25 Aug 2023	HC Wainwright & Co.	Reiterates	Buy	$1.00
16 May 2023	HC Wainwright & Co.	Reiterates	Buy	$1.00
18 Apr 2023	HC Wainwright & Co.	Reiterates	Buy	$1.00
4 Apr 2023	HC Wainwright & Co.	Maintains	Buy	$1.50 → $1.00
16 Nov 2022	HC Wainwright & Co.	Maintains	Buy	$2.00 → $1.50
18 May 2022	HC Wainwright & Co.	Maintains	Buy	—
17 Nov 2021	HC Wainwright & Co.	Maintains	Buy	—
16 Feb 2021	HC Wainwright & Co.	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XWEL appears on the weeks it earns a place.

Estimates

XWEL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

XWELL, Inc. (XWEL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.2×
Price / sales: 0.3×
Price / book: 20.2×
EV / EBITDA: −1.5×

Growth & margins

Revenue growth (YoY): −7.1%
Earnings growth (YoY): −5.5%
Gross margin: 35.4%
Operating margin: −26.1%
Net margin: −82.9%

Returns & dividend

Return on equity: −361.4%
Return on assets: −31.4%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

XWELL, Inc. (XWEL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

XWELL, Inc. has a market value of $8.9M and an enterprise value of $14.6M.
Revenue in the twelve months to 31 Mar 2026: $28.8M. The latest quarter shrank 7.1% year on year.
Net income over the same four quarters: −$22.5M, a −78.2% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$12.1M, after $2.9M of capital spending.
Shares outstanding: 7.9M.
Trailing P/E: −0.2×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.
XWELL, Inc. employs 175 people — $165K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

XWEL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research

Company	Market cap	TKN rank
XWELXWELL, Inc.	$8.9M	39
MBAICheck-Cap Ltd.	$10.9M	7
NDRAENDRA Life Sciences, Inc.	$6.7M	37
ADVBAdvanced Biomed, Inc.	$13.4M	16
ISPCiSpecimen, Inc.	$4.3M	23
BIAFbioAffinity Technologies, Inc.	$3.2M	16
PRPOPrecipio, Inc.	$53.3M	52

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own XWELL, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XWEL news & analysis

XWELL Appoints Global Energy and Capital Markets Leader Gerard Reid to its Board of Directors

GlobeNewsWire · 5 Aug 2026neutral

XWELL, Inc. announced the appointment of Gerard Reid to its Board of Directors, effective immediately. Separately, Ezra Ernst resigned as a director to focus on his responsibilities as the company's President and Chief Executive Officer.

Why it matters — XWELL watchers would care because the board's composition is changing, with a new director joining and the CEO stepping off the board to focus on his executive role.

FAQ

Frequently asked questions about XWEL stock

How does Ticker Nerd's model rank XWEL?

As at 22 Aug 2026, XWELL, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).

What is the XWEL stock forecast for 2030?

No analyst covering XWELL, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XWEL are extrapolating price history, which says nothing about the business.

What does XWELL, Inc. do?

Xwell Inc. is a health and wellness holding company that operates premium spa and wellness services primarily at airport locations across the United States and internationally.

What is the latest news on XWEL?

The most recent item we track (GlobeNewsWire, 5 Aug 2026): "XWELL Appoints Global Energy and Capital Markets Leader Gerard Reid to its Board of Directors". XWELL, Inc. announced the appointment of Gerard Reid to its Board of Directors, effective immediately. Separately, Ezra Ernst resigned as a director to focus on his responsibilities as the company's President and Chief Executive Officer.

Company

About XWELL, Inc.

Xwell Inc. is a health and wellness holding company that operates premium spa and wellness services primarily at airport locations across the United States and internationally. The company functions through four main business segments: XpresSpa, which provides travelers with massage, nail care, and skincare services along with spa and travel products; XpresTest, which offers COVID-19 diagnostic testing and screening services through partnership with the CDC; Naples Wax Center, featuring face and body waxing alongside skincare and cosmetic products; and Treat, a travel health and wellness brand delivering in-airport spa experiences. Xwell serves the traveling public and airport employees through physical stores and kiosks, as well as online channels. The company caters to consumers seeking wellness and relaxation services while in transit, positioning itself as a convenient provider of premium health and beauty services in airport environments. Headquartered in New York, Xwell operates in the healthcare and diagnostics sectors.

CEO Mr. Ezra T. Ernst · 175 employees · United States · https://www.xwell.com